#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


Text=Neural Correlates of Auditory Verbal Hallucinations in Schizophrenia and the Therapeutic Response to Theta-Burst Transcranial Magnetic Stimulation Abstract Auditory verbal hallucinations (AVHs) are a core symptom of schizophrenia, and resistant to antipsychotic medication in a substantial proportion of patients.
1-1	0-6	Neural	_
1-2	7-17	Correlates	_
1-3	18-20	of	_
1-4	21-29	Auditory	_
1-5	30-36	Verbal	_
1-6	37-51	Hallucinations	_
1-7	52-54	in	_
1-8	55-68	Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-9	69-72	and	_
1-10	73-76	the	_
1-11	77-88	Therapeutic	_
1-12	89-97	Response	_
1-13	98-100	to	_
1-14	101-112	Theta-Burst	_
1-15	113-125	Transcranial	http://maven.renci.org/NeuroBridge/neurobridge#AuditoryHallucinationsSubscaleofPsychoticSymptomsRatingScale
1-16	126-134	Magnetic	http://maven.renci.org/NeuroBridge/neurobridge#AuditoryHallucinationsSubscaleofPsychoticSymptomsRatingScale
1-17	135-146	Stimulation	http://maven.renci.org/NeuroBridge/neurobridge#AuditoryHallucinationsSubscaleofPsychoticSymptomsRatingScale
1-18	147-155	Abstract	http://maven.renci.org/NeuroBridge/neurobridge#AuditoryHallucinationsSubscaleofPsychoticSymptomsRatingScale
1-19	156-164	Auditory	http://maven.renci.org/NeuroBridge/neurobridge#AuditoryHallucinationsSubscaleofPsychoticSymptomsRatingScale
1-20	165-171	verbal	http://maven.renci.org/NeuroBridge/neurobridge#AuditoryHallucinationsSubscaleofPsychoticSymptomsRatingScale
1-21	172-186	hallucinations	http://maven.renci.org/NeuroBridge/neurobridge#AuditoryHallucinationsSubscaleofPsychoticSymptomsRatingScale
1-22	187-188	(	http://maven.renci.org/NeuroBridge/neurobridge#AuditoryHallucinationsSubscaleofPsychoticSymptomsRatingScale
1-23	189-193	AVHs	http://maven.renci.org/NeuroBridge/neurobridge#AuditoryHallucinationsSubscaleofPsychoticSymptomsRatingScale
1-24	194-195	)	http://maven.renci.org/NeuroBridge/neurobridge#AuditoryHallucinationsSubscaleofPsychoticSymptomsRatingScale
1-25	196-199	are	_
1-26	200-201	a	_
1-27	202-206	core	_
1-28	207-214	symptom	_
1-29	215-217	of	_
1-30	218-231	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-31	232-233	,	_
1-32	234-237	and	_
1-33	238-247	resistant	_
1-34	248-250	to	_
1-35	251-264	antipsychotic	_
1-36	265-275	medication	_
1-37	276-278	in	_
1-38	279-280	a	_
1-39	281-292	substantial	_
1-40	293-303	proportion	_
1-41	304-306	of	_
1-42	307-315	patients	_
1-43	316-317	.	_

Text=This study aimed to investigate the neural correlates of AVHs in schizophrenia patients and its response to a modified continuous theta-burst stimulation (cTBS) by transcranial magnetic stimulation.
2-1	318-322	This	_
2-2	323-328	study	_
2-3	329-334	aimed	_
2-4	335-337	to	_
2-5	338-349	investigate	_
2-6	350-353	the	_
2-7	354-360	neural	_
2-8	361-371	correlates	_
2-9	372-374	of	_
2-10	375-379	AVHs	_
2-11	380-382	in	_
2-12	383-396	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
2-13	397-405	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
2-14	406-409	and	_
2-15	410-413	its	_
2-16	414-422	response	_
2-17	423-425	to	_
2-18	426-427	a	_
2-19	428-436	modified	_
2-20	437-447	continuous	_
2-21	448-459	theta-burst	_
2-22	460-471	stimulation	_
2-23	472-473	(	_
2-24	474-478	cTBS	_
2-25	479-480	)	_
2-26	481-483	by	_
2-27	484-496	transcranial	_
2-28	497-505	magnetic	_
2-29	506-517	stimulation	_
2-30	518-519	.	_

Text=In a cross-sectional experiment, resting-state functional magnetic resonance images were collected from 31 AVH schizophrenia patients, 26 non-AVH schizophrenia patients, and 33 sex-/age-matched healthy controls (HCs).
3-1	520-522	In	_
3-2	523-524	a	_
3-3	525-540	cross-sectional	_
3-4	541-551	experiment	_
3-5	552-553	,	_
3-6	554-567	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-7	568-578	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-8	579-587	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-9	588-597	resonance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-10	598-604	images	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-11	605-609	were	_
3-12	610-619	collected	_
3-13	620-624	from	_
3-14	625-627	31	_
3-15	628-631	AVH	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
3-16	632-645	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
3-17	646-654	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
3-18	655-656	,	_
3-19	657-659	26	_
3-20	660-667	non-AVH	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
3-21	668-681	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
3-22	682-690	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
3-23	691-692	,	_
3-24	693-696	and	_
3-25	697-699	33	_
3-26	700-716	sex-/age-matched	_
3-27	717-724	healthy	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
3-28	725-733	controls	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
3-29	734-735	(	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
3-30	736-739	HCs	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
3-31	740-741	)	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
3-32	742-743	.	_

Text=Functional connectivity strength (FCS) maps were compared among groups by 1-way analysis of variance (ANOVA).
4-1	744-754	Functional	_
4-2	755-767	connectivity	_
4-3	768-776	strength	_
4-4	777-778	(	_
4-5	779-782	FCS	_
4-6	783-784	)	_
4-7	785-789	maps	_
4-8	790-794	were	_
4-9	795-803	compared	_
4-10	804-809	among	_
4-11	810-816	groups	_
4-12	817-819	by	_
4-13	820-825	1-way	_
4-14	826-834	analysis	_
4-15	835-837	of	_
4-16	838-846	variance	_
4-17	847-848	(	_
4-18	849-854	ANOVA	_
4-19	855-856	)	_
4-20	857-858	.	_

Text=In a longitudinal experiment, 16 and 11 AVH patients received real and sham cTBS treatment for 15 days, respectively.
5-1	859-861	In	_
5-2	862-863	a	_
5-3	864-876	longitudinal	_
5-4	877-887	experiment	_
5-5	888-889	,	_
5-6	890-892	16	_
5-7	893-896	and	_
5-8	897-899	11	_
5-9	900-903	AVH	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
5-10	904-912	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
5-11	913-921	received	_
5-12	922-926	real	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
5-13	927-930	and	_
5-14	931-935	sham	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
5-15	936-940	cTBS	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
5-16	941-950	treatment	_
5-17	951-954	for	_
5-18	955-957	15	_
5-19	958-962	days	_
5-20	963-964	,	_
5-21	965-977	respectively	_
5-22	978-979	.	_

Text=Notably, this was not a randomized control trail.
6-1	980-987	Notably	_
6-2	988-989	,	_
6-3	990-994	this	_
6-4	995-998	was	_
6-5	999-1002	not	_
6-6	1003-1004	a	_
6-7	1005-1015	randomized	_
6-8	1016-1023	control	_
6-9	1024-1029	trail	_
6-10	1030-1031	.	_

Text=Changes in AVH and FCS were analyzed by 2-way ANOVA and 2-sample t-test, respectively.
7-1	1032-1039	Changes	_
7-2	1040-1042	in	_
7-3	1043-1046	AVH	_
7-4	1047-1050	and	_
7-5	1051-1054	FCS	_
7-6	1055-1059	were	_
7-7	1060-1068	analyzed	_
7-8	1069-1071	by	_
7-9	1072-1077	2-way	_
7-10	1078-1083	ANOVA	_
7-11	1084-1087	and	_
7-12	1088-1096	2-sample	_
7-13	1097-1103	t-test	_
7-14	1104-1105	,	_
7-15	1106-1118	respectively	_
7-16	1119-1120	.	_

Text=In the cross-sectional experiment, comparison of FCS maps identified 8 clusters among groups, but only one cluster (in left cerebellum) differed significantly in AVH patients compared to both HCs and non-AVH patients.
8-1	1121-1123	In	_
8-2	1124-1127	the	_
8-3	1128-1143	cross-sectional	_
8-4	1144-1154	experiment	_
8-5	1155-1156	,	_
8-6	1157-1167	comparison	_
8-7	1168-1170	of	_
8-8	1171-1174	FCS	_
8-9	1175-1179	maps	_
8-10	1180-1190	identified	_
8-11	1191-1192	8	_
8-12	1193-1201	clusters	_
8-13	1202-1207	among	_
8-14	1208-1214	groups	_
8-15	1215-1216	,	_
8-16	1217-1220	but	_
8-17	1221-1225	only	_
8-18	1226-1229	one	_
8-19	1230-1237	cluster	_
8-20	1238-1239	(	_
8-21	1240-1242	in	_
8-22	1243-1247	left	_
8-23	1248-1258	cerebellum	_
8-24	1259-1260	)	_
8-25	1261-1269	differed	_
8-26	1270-1283	significantly	_
8-27	1284-1286	in	_
8-28	1287-1290	AVH	http://maven.renci.org/NeuroBridge/neurobridge#Thing
8-29	1291-1299	patients	_
8-30	1300-1308	compared	_
8-31	1309-1311	to	_
8-32	1312-1316	both	_
8-33	1317-1320	HCs	http://maven.renci.org/NeuroBridge/neurobridge#Thing
8-34	1321-1324	and	_
8-35	1325-1332	non-AVH	_
8-36	1333-1341	patients	_
8-37	1342-1343	.	_

Text=In the longitudinal experiment, the real cTBS group showed a greater improvement in symptoms and a larger FCS decrease in left cerebellum than the sham group.
9-1	1344-1346	In	_
9-2	1347-1350	the	_
9-3	1351-1363	longitudinal	_
9-4	1364-1374	experiment	_
9-5	1375-1376	,	_
9-6	1377-1380	the	_
9-7	1381-1385	real	_
9-8	1386-1390	cTBS	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
9-9	1391-1396	group	_
9-10	1397-1403	showed	_
9-11	1404-1405	a	_
9-12	1406-1413	greater	_
9-13	1414-1425	improvement	_
9-14	1426-1428	in	_
9-15	1429-1437	symptoms	_
9-16	1438-1441	and	_
9-17	1442-1443	a	_
9-18	1444-1450	larger	_
9-19	1451-1454	FCS	_
9-20	1455-1463	decrease	_
9-21	1464-1466	in	_
9-22	1467-1471	left	_
9-23	1472-1482	cerebellum	_
9-24	1483-1487	than	_
9-25	1488-1491	the	_
9-26	1492-1496	sham	_
9-27	1497-1502	group	_
9-28	1503-1504	.	_

Text=Pearson ’ s correlation analysis indicated that baseline FCS of the overlapping cerebellum cluster (between the cross-sectional and longitudinal findings) was negatively correlated with symptom improvement in the real treatment group.
10-1	1505-1512	Pearson	_
10-2	1513-1514	’	_
10-3	1515-1516	s	_
10-4	1517-1528	correlation	_
10-5	1529-1537	analysis	_
10-6	1538-1547	indicated	_
10-7	1548-1552	that	_
10-8	1553-1561	baseline	_
10-9	1562-1565	FCS	_
10-10	1566-1568	of	_
10-11	1569-1572	the	_
10-12	1573-1584	overlapping	_
10-13	1585-1595	cerebellum	_
10-14	1596-1603	cluster	_
10-15	1604-1605	(	_
10-16	1606-1613	between	_
10-17	1614-1617	the	_
10-18	1618-1633	cross-sectional	_
10-19	1634-1637	and	_
10-20	1638-1650	longitudinal	_
10-21	1651-1659	findings	_
10-22	1660-1661	)	_
10-23	1662-1665	was	_
10-24	1666-1676	negatively	_
10-25	1677-1687	correlated	_
10-26	1688-1692	with	_
10-27	1693-1700	symptom	_
10-28	1701-1712	improvement	_
10-29	1713-1715	in	_
10-30	1716-1719	the	_
10-31	1720-1724	real	_
10-32	1725-1734	treatment	_
10-33	1735-1740	group	_
10-34	1741-1742	.	_

Text=These findings emphasize the role of the left cerebellum in both the pathophysiology and clinical treatment of AVHs in schizophrenia patients.
11-1	1743-1748	These	_
11-2	1749-1757	findings	_
11-3	1758-1767	emphasize	_
11-4	1768-1771	the	_
11-5	1772-1776	role	_
11-6	1777-1779	of	_
11-7	1780-1783	the	_
11-8	1784-1788	left	_
11-9	1789-1799	cerebellum	_
11-10	1800-1802	in	_
11-11	1803-1807	both	_
11-12	1808-1811	the	_
11-13	1812-1827	pathophysiology	_
11-14	1828-1831	and	_
11-15	1832-1840	clinical	_
11-16	1841-1850	treatment	_
11-17	1851-1853	of	_
11-18	1854-1858	AVHs	http://maven.renci.org/NeuroBridge/neurobridge#Thing
11-19	1859-1861	in	_
11-20	1862-1875	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
11-21	1876-1884	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
11-22	1885-1886	.	_

Text=Materials and Methods This study is composed of cross-sectional and longitudinal experiments.
12-1	1887-1896	Materials	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
12-2	1897-1900	and	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
12-3	1901-1908	Methods	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
12-4	1909-1913	This	_
12-5	1914-1919	study	_
12-6	1920-1922	is	_
12-7	1923-1931	composed	_
12-8	1932-1934	of	_
12-9	1935-1950	cross-sectional	_
12-10	1951-1954	and	_
12-11	1955-1967	longitudinal	_
12-12	1968-1979	experiments	_
12-13	1980-1981	.	_

Text=All participants provided written informed consent before experiments.
13-1	1982-1985	All	_
13-2	1986-1998	participants	_
13-3	1999-2007	provided	_
13-4	2008-2015	written	_
13-5	2016-2024	informed	_
13-6	2025-2032	consent	_
13-7	2033-2039	before	_
13-8	2040-2051	experiments	_
13-9	2052-2053	.	_

Text=The cross-sectional experiment investigated the neural correlates of AVH by comparing FCS maps among AVH, non-AVH, and HC participants.
14-1	2054-2057	The	_
14-2	2058-2073	cross-sectional	_
14-3	2074-2084	experiment	_
14-4	2085-2097	investigated	_
14-5	2098-2101	the	_
14-6	2102-2108	neural	_
14-7	2109-2119	correlates	_
14-8	2120-2122	of	_
14-9	2123-2126	AVH	_
14-10	2127-2129	by	_
14-11	2130-2139	comparing	_
14-12	2140-2143	FCS	_
14-13	2144-2148	maps	_
14-14	2149-2154	among	_
14-15	2155-2158	AVH	_
14-16	2159-2160	,	_
14-17	2161-2168	non-AVH	_
14-18	2169-2170	,	_
14-19	2171-2174	and	_
14-20	2175-2177	HC	_
14-21	2178-2190	participants	_
14-22	2191-2192	.	_

Text=The longitudinal experiment tested the clinical efficacy of a modified rTMS protocol and its underlying neural mechanism by rs-fMRI.
15-1	2193-2196	The	_
15-2	2197-2209	longitudinal	_
15-3	2210-2220	experiment	_
15-4	2221-2227	tested	_
15-5	2228-2231	the	_
15-6	2232-2240	clinical	_
15-7	2241-2249	efficacy	_
15-8	2250-2252	of	_
15-9	2253-2254	a	_
15-10	2255-2263	modified	_
15-11	2264-2268	rTMS	_
15-12	2269-2277	protocol	_
15-13	2278-2281	and	_
15-14	2282-2285	its	_
15-15	2286-2296	underlying	_
15-16	2297-2303	neural	_
15-17	2304-2313	mechanism	_
15-18	2314-2316	by	_
15-19	2317-2324	rs-fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
15-20	2325-2326	.	_

Text=Finally, a spatial overlap map was produced, utilizing the fMRI findings of both experiments, to evaluate the rTMS mechanism in terms of baseline abnormality (figure 1).
16-1	2327-2334	Finally	_
16-2	2335-2336	,	_
16-3	2337-2338	a	_
16-4	2339-2346	spatial	_
16-5	2347-2354	overlap	_
16-6	2355-2358	map	_
16-7	2359-2362	was	_
16-8	2363-2371	produced	_
16-9	2372-2373	,	_
16-10	2374-2383	utilizing	_
16-11	2384-2387	the	_
16-12	2388-2392	fMRI	_
16-13	2393-2401	findings	_
16-14	2402-2404	of	_
16-15	2405-2409	both	_
16-16	2410-2421	experiments	_
16-17	2422-2423	,	_
16-18	2424-2426	to	_
16-19	2427-2435	evaluate	_
16-20	2436-2439	the	_
16-21	2440-2444	rTMS	_
16-22	2445-2454	mechanism	_
16-23	2455-2457	in	_
16-24	2458-2463	terms	_
16-25	2464-2466	of	_
16-26	2467-2475	baseline	_
16-27	2476-2487	abnormality	_
16-28	2488-2489	(	_
16-29	2490-2496	figure	_
16-30	2497-2498	1	_
16-31	2499-2500	)	_
16-32	2501-2502	.	_

Text=Notably, the longitudinal rTMS experiment was not a randomized control trail, although both real and sham treatment were performed in this part.
17-1	2503-2510	Notably	_
17-2	2511-2512	,	_
17-3	2513-2516	the	_
17-4	2517-2529	longitudinal	_
17-5	2530-2534	rTMS	_
17-6	2535-2545	experiment	_
17-7	2546-2549	was	_
17-8	2550-2553	not	_
17-9	2554-2555	a	_
17-10	2556-2566	randomized	_
17-11	2567-2574	control	_
17-12	2575-2580	trail	_
17-13	2581-2582	,	_
17-14	2583-2591	although	_
17-15	2592-2596	both	_
17-16	2597-2601	real	_
17-17	2602-2605	and	_
17-18	2606-2610	sham	_
17-19	2611-2620	treatment	_
17-20	2621-2625	were	_
17-21	2626-2635	performed	_
17-22	2636-2638	in	_
17-23	2639-2643	this	_
17-24	2644-2648	part	_
17-25	2649-2650	.	_

Text=Participants A total of 57 patients diagnosed with refractory schizophrenia at the Anhui Mental Health Center (Hefei, China) were consecutively enrolled in this study (supplementary tables E1–E3).
18-1	2651-2663	Participants	_
18-2	2664-2665	A	_
18-3	2666-2671	total	_
18-4	2672-2674	of	_
18-5	2675-2677	57	_
18-6	2678-2686	patients	_
18-7	2687-2696	diagnosed	_
18-8	2697-2701	with	_
18-9	2702-2712	refractory	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
18-10	2713-2726	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
18-11	2727-2729	at	_
18-12	2730-2733	the	_
18-13	2734-2739	Anhui	_
18-14	2740-2746	Mental	_
18-15	2747-2753	Health	_
18-16	2754-2760	Center	_
18-17	2761-2762	(	_
18-18	2763-2768	Hefei	_
18-19	2769-2770	,	_
18-20	2771-2776	China	_
18-21	2777-2778	)	_
18-22	2779-2783	were	_
18-23	2784-2797	consecutively	_
18-24	2798-2806	enrolled	_
18-25	2807-2809	in	_
18-26	2810-2814	this	_
18-27	2815-2820	study	_
18-28	2821-2822	(	_
18-29	2823-2836	supplementary	_
18-30	2837-2843	tables	_
18-31	2844-2849	E1–E3	_
18-32	2850-2851	)	_
18-33	2852-2853	.	_

Text=The study protocol was reviewed and approved by the Medical Ethics Committee of Anhui Medical University, Hefei, China.
19-1	2854-2857	The	_
19-2	2858-2863	study	_
19-3	2864-2872	protocol	_
19-4	2873-2876	was	_
19-5	2877-2885	reviewed	_
19-6	2886-2889	and	_
19-7	2890-2898	approved	_
19-8	2899-2901	by	_
19-9	2902-2905	the	_
19-10	2906-2913	Medical	_
19-11	2914-2920	Ethics	_
19-12	2921-2930	Committee	_
19-13	2931-2933	of	_
19-14	2934-2939	Anhui	_
19-15	2940-2947	Medical	_
19-16	2948-2958	University	_
19-17	2959-2960	,	_
19-18	2961-2966	Hefei	_
19-19	2967-2968	,	_
19-20	2969-2974	China	_
19-21	2975-2976	.	_

Text=All participants satisfied the following inclusion criteria: (1) diagnosis of schizophrenia using the Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (SCID-IV), (2) were taking stable doses of psychotropic medication for at least 8 weeks before the study, and (3) verbal intelligence quotient> 85 as measured utilizing a Chinese version of the National Adult Reading Test.
20-1	2977-2980	All	_
20-2	2981-2993	participants	_
20-3	2994-3003	satisfied	_
20-4	3004-3007	the	_
20-5	3008-3017	following	_
20-6	3018-3027	inclusion	_
20-7	3028-3036	criteria	_
20-8	3037-3038	:	_
20-9	3039-3040	(	_
20-10	3041-3042	1	_
20-11	3043-3044	)	_
20-12	3045-3054	diagnosis	_
20-13	3055-3057	of	_
20-14	3058-3071	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
20-15	3072-3077	using	_
20-16	3078-3081	the	_
20-17	3082-3092	Structured	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
20-18	3093-3101	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
20-19	3102-3111	Interview	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
20-20	3112-3115	for	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
20-21	3116-3119	the	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
20-22	3120-3130	Diagnostic	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
20-23	3131-3134	and	_
20-24	3135-3146	Statistical	_
20-25	3147-3153	Manual	http://maven.renci.org/NeuroBridge/neurobridge#MercurySphygmomanometer
20-26	3154-3156	of	_
20-27	3157-3163	Mental	_
20-28	3164-3173	Disorders	_
20-29	3174-3175	,	_
20-30	3176-3182	Fourth	_
20-31	3183-3190	Edition	_
20-32	3191-3192	(	_
20-33	3193-3200	SCID-IV	_
20-34	3201-3202	)	_
20-35	3203-3204	,	_
20-36	3205-3206	(	_
20-37	3207-3208	2	_
20-38	3209-3210	)	_
20-39	3211-3215	were	_
20-40	3216-3222	taking	_
20-41	3223-3229	stable	_
20-42	3230-3235	doses	_
20-43	3236-3238	of	_
20-44	3239-3251	psychotropic	_
20-45	3252-3262	medication	_
20-46	3263-3266	for	_
20-47	3267-3269	at	_
20-48	3270-3275	least	_
20-49	3276-3277	8	_
20-50	3278-3283	weeks	_
20-51	3284-3290	before	_
20-52	3291-3294	the	_
20-53	3295-3300	study	_
20-54	3301-3302	,	_
20-55	3303-3306	and	_
20-56	3307-3308	(	_
20-57	3309-3310	3	_
20-58	3311-3312	)	_
20-59	3313-3319	verbal	_
20-60	3320-3332	intelligence	_
20-61	3333-3341	quotient	_
20-62	3342-3343	>	_
20-63	3344-3346	85	_
20-64	3347-3349	as	_
20-65	3350-3358	measured	_
20-66	3359-3368	utilizing	_
20-67	3369-3370	a	_
20-68	3371-3378	Chinese	_
20-69	3379-3386	version	_
20-70	3387-3389	of	_
20-71	3390-3393	the	_
20-72	3394-3402	National	_
20-73	3403-3408	Adult	_
20-74	3409-3416	Reading	_
20-75	3417-3421	Test	_
20-76	3422-3423	.	_

Text=Exclusion criteria were as follows: (1) history of significant head trauma or neurological disorders, (2) alcohol or drug abuse, (3) focal brain lesions on T1- or T2-weighted fluid-attenuated inversion-recovery magnetic resonance images, (4) recent aggression or other forms of behavioral dysfunction, (5) head motion exceeding 3 mm in translation or 3° in rotation during rs-fMRI scanning, or (6) Hamilton Anxiety Rating Scale or Hamilton Depression Rating Scale score> 7.
21-1	3424-3433	Exclusion	_
21-2	3434-3442	criteria	_
21-3	3443-3447	were	_
21-4	3448-3450	as	_
21-5	3451-3458	follows	_
21-6	3459-3460	:	_
21-7	3461-3462	(	_
21-8	3463-3464	1	_
21-9	3465-3466	)	_
21-10	3467-3474	history	_
21-11	3475-3477	of	_
21-12	3478-3489	significant	_
21-13	3490-3494	head	_
21-14	3495-3501	trauma	_
21-15	3502-3504	or	_
21-16	3505-3517	neurological	_
21-17	3518-3527	disorders	_
21-18	3528-3529	,	_
21-19	3530-3531	(	_
21-20	3532-3533	2	_
21-21	3534-3535	)	_
21-22	3536-3543	alcohol	_
21-23	3544-3546	or	_
21-24	3547-3551	drug	_
21-25	3552-3557	abuse	_
21-26	3558-3559	,	_
21-27	3560-3561	(	_
21-28	3562-3563	3	_
21-29	3564-3565	)	_
21-30	3566-3571	focal	_
21-31	3572-3577	brain	_
21-32	3578-3585	lesions	_
21-33	3586-3588	on	_
21-34	3589-3592	T1-	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
21-35	3593-3595	or	_
21-36	3596-3607	T2-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging
21-37	3608-3624	fluid-attenuated	_
21-38	3625-3643	inversion-recovery	http://maven.renci.org/NeuroBridge/neurobridge#FluidAttenuatedInversionRecoveryImaging
21-39	3644-3652	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FluidAttenuatedInversionRecoveryImaging
21-40	3653-3662	resonance	http://maven.renci.org/NeuroBridge/neurobridge#FluidAttenuatedInversionRecoveryImaging
21-41	3663-3669	images	http://maven.renci.org/NeuroBridge/neurobridge#FluidAttenuatedInversionRecoveryImaging
21-42	3670-3671	,	_
21-43	3672-3673	(	_
21-44	3674-3675	4	_
21-45	3676-3677	)	_
21-46	3678-3684	recent	_
21-47	3685-3695	aggression	_
21-48	3696-3698	or	_
21-49	3699-3704	other	_
21-50	3705-3710	forms	_
21-51	3711-3713	of	_
21-52	3714-3724	behavioral	_
21-53	3725-3736	dysfunction	_
21-54	3737-3738	,	_
21-55	3739-3740	(	_
21-56	3741-3742	5	_
21-57	3743-3744	)	_
21-58	3745-3749	head	_
21-59	3750-3756	motion	_
21-60	3757-3766	exceeding	_
21-61	3767-3768	3	_
21-62	3769-3771	mm	_
21-63	3772-3774	in	_
21-64	3775-3786	translation	_
21-65	3787-3789	or	_
21-66	3790-3792	3°	_
21-67	3793-3795	in	_
21-68	3796-3804	rotation	_
21-69	3805-3811	during	_
21-70	3812-3819	rs-fMRI	_
21-71	3820-3828	scanning	_
21-72	3829-3830	,	_
21-73	3831-3833	or	_
21-74	3834-3835	(	_
21-75	3836-3837	6	_
21-76	3838-3839	)	_
21-77	3840-3848	Hamilton	http://maven.renci.org/NeuroBridge/neurobridge#HamiltonAnxietyRatingScale
21-78	3849-3856	Anxiety	http://maven.renci.org/NeuroBridge/neurobridge#HamiltonAnxietyRatingScale
21-79	3857-3863	Rating	http://maven.renci.org/NeuroBridge/neurobridge#HamiltonAnxietyRatingScale
21-80	3864-3869	Scale	http://maven.renci.org/NeuroBridge/neurobridge#HamiltonAnxietyRatingScale
21-81	3870-3872	or	_
21-82	3873-3881	Hamilton	http://maven.renci.org/NeuroBridge/neurobridge#DepressionRatingScale
21-83	3882-3892	Depression	http://maven.renci.org/NeuroBridge/neurobridge#DepressionRatingScale
21-84	3893-3899	Rating	http://maven.renci.org/NeuroBridge/neurobridge#DepressionRatingScale
21-85	3900-3905	Scale	_
21-86	3906-3911	score	_
21-87	3912-3913	>	_
21-88	3914-3915	7	_
21-89	3916-3917	.	_

Text=Patients were further classified into 2 groups: those reporting AVHs of spoken speech at least 5 times per day during the preceding 8 weeks (AVH group, n = 31) and patients who had not experienced AVHs (or olfactory, gustatory, tactile hallucination) since the diagnosis of schizophrenia or within 5 years before scans (non-AVH group, n = 26).
22-1	3918-3926	Patients	_
22-2	3927-3931	were	_
22-3	3932-3939	further	_
22-4	3940-3950	classified	_
22-5	3951-3955	into	_
22-6	3956-3957	2	_
22-7	3958-3964	groups	_
22-8	3965-3966	:	_
22-9	3967-3972	those	_
22-10	3973-3982	reporting	_
22-11	3983-3987	AVHs	_
22-12	3988-3990	of	_
22-13	3991-3997	spoken	_
22-14	3998-4004	speech	_
22-15	4005-4007	at	_
22-16	4008-4013	least	_
22-17	4014-4015	5	_
22-18	4016-4021	times	_
22-19	4022-4025	per	_
22-20	4026-4029	day	_
22-21	4030-4036	during	_
22-22	4037-4040	the	_
22-23	4041-4050	preceding	_
22-24	4051-4052	8	_
22-25	4053-4058	weeks	_
22-26	4059-4060	(	_
22-27	4061-4064	AVH	http://maven.renci.org/NeuroBridge/neurobridge#Thing
22-28	4065-4070	group	_
22-29	4071-4072	,	_
22-30	4073-4074	n	_
22-31	4075-4076	=	_
22-32	4077-4079	31	_
22-33	4080-4081	)	_
22-34	4082-4085	and	_
22-35	4086-4094	patients	_
22-36	4095-4098	who	_
22-37	4099-4102	had	_
22-38	4103-4106	not	_
22-39	4107-4118	experienced	_
22-40	4119-4123	AVHs	_
22-41	4124-4125	(	_
22-42	4126-4128	or	_
22-43	4129-4138	olfactory	_
22-44	4139-4140	,	_
22-45	4141-4150	gustatory	_
22-46	4151-4152	,	_
22-47	4153-4160	tactile	_
22-48	4161-4174	hallucination	_
22-49	4175-4176	)	_
22-50	4177-4182	since	_
22-51	4183-4186	the	_
22-52	4187-4196	diagnosis	_
22-53	4197-4199	of	_
22-54	4200-4213	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
22-55	4214-4216	or	_
22-56	4217-4223	within	_
22-57	4224-4225	5	_
22-58	4226-4231	years	_
22-59	4232-4238	before	_
22-60	4239-4244	scans	_
22-61	4245-4246	(	_
22-62	4247-4254	non-AVH	_
22-63	4255-4260	group	_
22-64	4261-4262	,	_
22-65	4263-4264	n	_
22-66	4265-4266	=	_
22-67	4267-4269	26	_
22-68	4270-4271	)	_
22-69	4272-4273	.	_

Text=The most commonly positive syndromes of the non-AVH group were delusional disorder (n = 15), impulsion (n = 10), and restlessness (n = 8).
23-1	4274-4277	The	_
23-2	4278-4282	most	_
23-3	4283-4291	commonly	_
23-4	4292-4300	positive	_
23-5	4301-4310	syndromes	_
23-6	4311-4313	of	_
23-7	4314-4317	the	_
23-8	4318-4325	non-AVH	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
23-9	4326-4331	group	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
23-10	4332-4336	were	_
23-11	4337-4347	delusional	_
23-12	4348-4356	disorder	_
23-13	4357-4358	(	_
23-14	4359-4360	n	_
23-15	4361-4362	=	_
23-16	4363-4365	15	_
23-17	4366-4367	)	_
23-18	4368-4369	,	_
23-19	4370-4379	impulsion	_
23-20	4380-4381	(	_
23-21	4382-4383	n	_
23-22	4384-4385	=	_
23-23	4386-4388	10	_
23-24	4389-4390	)	_
23-25	4391-4392	,	_
23-26	4393-4396	and	_
23-27	4397-4409	restlessness	_
23-28	4410-4411	(	_
23-29	4412-4413	n	_
23-30	4414-4415	=	_
23-31	4416-4417	8	_
23-32	4418-4419	)	_
23-33	4420-4421	.	_

Text=All AVH patients were refractory, which may be defined as the experience of persistent daily hallucinations without remission despite antipsychotic medication administered at an adequate dosage for at least 12 weeks.
24-1	4422-4425	All	_
24-2	4426-4429	AVH	http://maven.renci.org/NeuroBridge/neurobridge#Thing
24-3	4430-4438	patients	_
24-4	4439-4443	were	_
24-5	4444-4454	refractory	_
24-6	4455-4456	,	_
24-7	4457-4462	which	_
24-8	4463-4466	may	_
24-9	4467-4469	be	_
24-10	4470-4477	defined	_
24-11	4478-4480	as	_
24-12	4481-4484	the	_
24-13	4485-4495	experience	_
24-14	4496-4498	of	_
24-15	4499-4509	persistent	_
24-16	4510-4515	daily	_
24-17	4516-4530	hallucinations	_
24-18	4531-4538	without	_
24-19	4539-4548	remission	_
24-20	4549-4556	despite	_
24-21	4557-4570	antipsychotic	_
24-22	4571-4581	medication	_
24-23	4582-4594	administered	_
24-24	4595-4597	at	_
24-25	4598-4600	an	_
24-26	4601-4609	adequate	_
24-27	4610-4616	dosage	_
24-28	4617-4620	for	_
24-29	4621-4623	at	_
24-30	4624-4629	least	_
24-31	4630-4632	12	_
24-32	4633-4638	weeks	_
24-33	4639-4640	.	_

Text=With regard to AVH patients participating in the longitudinal rTMS study, additional exclusion criteria included (1) age <18 years, (2) non-removable metal objects in or around head, or (3) prior history of seizure or history in first degree relatives.
25-1	4641-4645	With	_
25-2	4646-4652	regard	_
25-3	4653-4655	to	_
25-4	4656-4659	AVH	http://maven.renci.org/NeuroBridge/neurobridge#Thing
25-5	4660-4668	patients	_
25-6	4669-4682	participating	_
25-7	4683-4685	in	_
25-8	4686-4689	the	_
25-9	4690-4702	longitudinal	_
25-10	4703-4707	rTMS	_
25-11	4708-4713	study	_
25-12	4714-4715	,	_
25-13	4716-4726	additional	_
25-14	4727-4736	exclusion	_
25-15	4737-4745	criteria	_
25-16	4746-4754	included	_
25-17	4755-4756	(	_
25-18	4757-4758	1	_
25-19	4759-4760	)	_
25-20	4761-4764	age	_
25-21	4765-4766	<	_
25-22	4767-4769	18	_
25-23	4770-4775	years	_
25-24	4776-4777	,	_
25-25	4778-4779	(	_
25-26	4780-4781	2	_
25-27	4782-4783	)	_
25-28	4784-4797	non-removable	_
25-29	4798-4803	metal	_
25-30	4804-4811	objects	_
25-31	4812-4814	in	_
25-32	4815-4817	or	_
25-33	4818-4824	around	_
25-34	4825-4829	head	_
25-35	4830-4831	,	_
25-36	4832-4834	or	_
25-37	4835-4836	(	_
25-38	4837-4838	3	_
25-39	4839-4840	)	_
25-40	4841-4846	prior	_
25-41	4847-4854	history	_
25-42	4855-4857	of	_
25-43	4858-4865	seizure	_
25-44	4866-4868	or	_
25-45	4869-4876	history	_
25-46	4877-4879	in	_
25-47	4880-4885	first	_
25-48	4886-4892	degree	_
25-49	4893-4902	relatives	_
25-50	4903-4904	.	_

Text=Finally, 16 AVH patients provided their consent for real rTMS treatment.
26-1	4905-4912	Finally	_
26-2	4913-4914	,	_
26-3	4915-4917	16	_
26-4	4918-4921	AVH	http://maven.renci.org/NeuroBridge/neurobridge#Thing
26-5	4922-4930	patients	_
26-6	4931-4939	provided	_
26-7	4940-4945	their	_
26-8	4946-4953	consent	_
26-9	4954-4957	for	_
26-10	4958-4962	real	_
26-11	4963-4967	rTMS	http://maven.renci.org/NeuroBridge/neurobridge#Thing
26-12	4968-4977	treatment	_
26-13	4978-4979	.	_

Text=After the end of the rTMS treatment experiment, the researchers realized that a sham–control would be necessary to exclude the placebo effect of rTMS.
27-1	4980-4985	After	_
27-2	4986-4989	the	_
27-3	4990-4993	end	_
27-4	4994-4996	of	_
27-5	4997-5000	the	_
27-6	5001-5005	rTMS	_
27-7	5006-5015	treatment	_
27-8	5016-5026	experiment	_
27-9	5027-5028	,	_
27-10	5029-5032	the	_
27-11	5033-5044	researchers	_
27-12	5045-5053	realized	_
27-13	5054-5058	that	_
27-14	5059-5060	a	_
27-15	5061-5073	sham–control	_
27-16	5074-5079	would	_
27-17	5080-5082	be	_
27-18	5083-5092	necessary	_
27-19	5093-5095	to	_
27-20	5096-5103	exclude	_
27-21	5104-5107	the	_
27-22	5108-5115	placebo	_
27-23	5116-5122	effect	_
27-24	5123-5125	of	_
27-25	5126-5130	rTMS	_
27-26	5131-5132	.	_

Text=According to the primary results of real stimulation (see Results), a sample of 7 participants proved large enough to identify the treatment effect (alpha = 0.05, beta = 0.8).
28-1	5133-5142	According	_
28-2	5143-5145	to	_
28-3	5146-5149	the	_
28-4	5150-5157	primary	_
28-5	5158-5165	results	_
28-6	5166-5168	of	_
28-7	5169-5173	real	_
28-8	5174-5185	stimulation	_
28-9	5186-5187	(	_
28-10	5188-5191	see	_
28-11	5192-5199	Results	_
28-12	5200-5201	)	_
28-13	5202-5203	,	_
28-14	5204-5205	a	_
28-15	5206-5212	sample	_
28-16	5213-5215	of	_
28-17	5216-5217	7	_
28-18	5218-5230	participants	_
28-19	5231-5237	proved	_
28-20	5238-5243	large	_
28-21	5244-5250	enough	_
28-22	5251-5253	to	_
28-23	5254-5262	identify	_
28-24	5263-5266	the	_
28-25	5267-5276	treatment	_
28-26	5277-5283	effect	_
28-27	5284-5285	(	_
28-28	5286-5291	alpha	_
28-29	5292-5293	=	_
28-30	5294-5298	0.05	_
28-31	5299-5300	,	_
28-32	5301-5305	beta	_
28-33	5306-5307	=	_
28-34	5308-5311	0.8	_
28-35	5312-5313	)	_
28-36	5314-5315	.	_

Text=Fortunately, an interim inspection of another ongoing study (Randomized Clinical Trail [RCT] number: NCT02863094) allowed the researchers to collect data from 11 refractory AVH patients (meeting the inclusion and exclusion criteria of this study) who had received sham rTMS.
29-1	5316-5327	Fortunately	_
29-2	5328-5329	,	_
29-3	5330-5332	an	_
29-4	5333-5340	interim	_
29-5	5341-5351	inspection	_
29-6	5352-5354	of	_
29-7	5355-5362	another	_
29-8	5363-5370	ongoing	_
29-9	5371-5376	study	_
29-10	5377-5378	(	_
29-11	5379-5389	Randomized	_
29-12	5390-5398	Clinical	_
29-13	5399-5404	Trail	_
29-14	5405-5406	[	_
29-15	5407-5410	RCT	_
29-16	5411-5412	]	_
29-17	5413-5419	number	_
29-18	5420-5421	:	_
29-19	5422-5433	NCT02863094	_
29-20	5434-5435	)	_
29-21	5436-5443	allowed	_
29-22	5444-5447	the	_
29-23	5448-5459	researchers	_
29-24	5460-5462	to	_
29-25	5463-5470	collect	_
29-26	5471-5475	data	_
29-27	5476-5480	from	_
29-28	5481-5483	11	_
29-29	5484-5494	refractory	http://maven.renci.org/NeuroBridge/neurobridge#FactorialTrial
29-30	5495-5498	AVH	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
29-31	5499-5507	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
29-32	5508-5509	(	_
29-33	5510-5517	meeting	_
29-34	5518-5521	the	_
29-35	5522-5531	inclusion	_
29-36	5532-5535	and	_
29-37	5536-5545	exclusion	_
29-38	5546-5554	criteria	_
29-39	5555-5557	of	_
29-40	5558-5562	this	_
29-41	5563-5568	study	_
29-42	5569-5570	)	_
29-43	5571-5574	who	_
29-44	5575-5578	had	_
29-45	5579-5587	received	_
29-46	5588-5592	sham	_
29-47	5593-5597	rTMS	_
29-48	5598-5599	.	_

Text=Thus, their data were utilized in the sham–control group in the current study.
30-1	5600-5604	Thus	_
30-2	5605-5606	,	_
30-3	5607-5612	their	_
30-4	5613-5617	data	_
30-5	5618-5622	were	_
30-6	5623-5631	utilized	_
30-7	5632-5634	in	_
30-8	5635-5638	the	_
30-9	5639-5651	sham–control	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
30-10	5652-5657	group	_
30-11	5658-5660	in	_
30-12	5661-5664	the	_
30-13	5665-5672	current	_
30-14	5673-5678	study	_
30-15	5679-5680	.	_

Text=Thirty-three HCs with no history of neurological or psychiatric illnesses were randomly recruited from the local community.
31-1	5681-5693	Thirty-three	_
31-2	5694-5697	HCs	http://maven.renci.org/NeuroBridge/neurobridge#Thing
31-3	5698-5702	with	_
31-4	5703-5705	no	_
31-5	5706-5713	history	_
31-6	5714-5716	of	_
31-7	5717-5729	neurological	_
31-8	5730-5732	or	_
31-9	5733-5744	psychiatric	_
31-10	5745-5754	illnesses	_
31-11	5755-5759	were	_
31-12	5760-5768	randomly	_
31-13	5769-5778	recruited	_
31-14	5779-5783	from	_
31-15	5784-5787	the	_
31-16	5788-5793	local	_
31-17	5794-5803	community	_
31-18	5804-5805	.	_

Text=This group exhibited no gross abnormalities on brain MR images.
32-1	5806-5810	This	_
32-2	5811-5816	group	_
32-3	5817-5826	exhibited	_
32-4	5827-5829	no	_
32-5	5830-5835	gross	_
32-6	5836-5849	abnormalities	_
32-7	5850-5852	on	_
32-8	5853-5858	brain	_
32-9	5859-5861	MR	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
32-10	5862-5868	images	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
32-11	5869-5870	.	_

Text=MRI Data Acquisition Magnetic resonance images were acquired from 2 scanners of the same type (3.0T, Discovery GE750w, General Electric).
33-1	5871-5874	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
33-2	5875-5879	Data	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
33-3	5880-5891	Acquisition	_
33-4	5892-5900	Magnetic	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
33-5	5901-5910	resonance	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
33-6	5911-5917	images	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
33-7	5918-5922	were	_
33-8	5923-5931	acquired	_
33-9	5932-5936	from	_
33-10	5937-5938	2	_
33-11	5939-5947	scanners	_
33-12	5948-5950	of	_
33-13	5951-5954	the	_
33-14	5955-5959	same	_
33-15	5960-5964	type	_
33-16	5965-5966	(	_
33-17	5967-5971	3.0T	_
33-18	5972-5973	,	_
33-19	5974-5983	Discovery	_
33-20	5984-5990	GE750w	_
33-21	5991-5992	,	_
33-22	5993-6000	General	_
33-23	6001-6009	Electric	_
33-24	6010-6011	)	_
33-25	6012-6013	.	_

Text=One scanner was used for the sham treatment group, and the other for the real treatment group and cross-sectional experiment.
34-1	6014-6017	One	_
34-2	6018-6025	scanner	_
34-3	6026-6029	was	_
34-4	6030-6034	used	_
34-5	6035-6038	for	_
34-6	6039-6042	the	_
34-7	6043-6047	sham	_
34-8	6048-6057	treatment	_
34-9	6058-6063	group	_
34-10	6064-6065	,	_
34-11	6066-6069	and	_
34-12	6070-6073	the	_
34-13	6074-6079	other	_
34-14	6080-6083	for	_
34-15	6084-6087	the	_
34-16	6088-6092	real	_
34-17	6093-6102	treatment	_
34-18	6103-6108	group	_
34-19	6109-6112	and	_
34-20	6113-6128	cross-sectional	_
34-21	6129-6139	experiment	_
34-22	6140-6141	.	_

Text=Details were outlined in supplementary materials.
35-1	6142-6149	Details	_
35-2	6150-6154	were	_
35-3	6155-6163	outlined	_
35-4	6164-6166	in	_
35-5	6167-6180	supplementary	_
35-6	6181-6190	materials	_
35-7	6191-6192	.	_

Text=Neuro-navigated rTMS The AVH patients made 17 study-related visits to the hospital.
36-1	6193-6208	Neuro-navigated	_
36-2	6209-6213	rTMS	http://maven.renci.org/NeuroBridge/neurobridge#Thing
36-3	6214-6217	The	_
36-4	6218-6221	AVH	http://maven.renci.org/NeuroBridge/neurobridge#Thing
36-5	6222-6230	patients	_
36-6	6231-6235	made	_
36-7	6236-6238	17	_
36-8	6239-6252	study-related	_
36-9	6253-6259	visits	_
36-10	6260-6262	to	_
36-11	6263-6266	the	_
36-12	6267-6275	hospital	_
36-13	6276-6277	.	_

Text=On the first and last visits, the researchers acquired MRI data and assessed neuropsychological conditions and clinical symptoms.
37-1	6278-6280	On	_
37-2	6281-6284	the	_
37-3	6285-6290	first	_
37-4	6291-6294	and	_
37-5	6295-6299	last	_
37-6	6300-6306	visits	_
37-7	6307-6308	,	_
37-8	6309-6312	the	_
37-9	6313-6324	researchers	_
37-10	6325-6333	acquired	_
37-11	6334-6337	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
37-12	6338-6342	data	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
37-13	6343-6346	and	_
37-14	6347-6355	assessed	_
37-15	6356-6374	neuropsychological	_
37-16	6375-6385	conditions	_
37-17	6386-6389	and	_
37-18	6390-6398	clinical	_
37-19	6399-6407	symptoms	_
37-20	6408-6409	.	_

Text=From the 2nd to 16th day, participants received 3 daily sessions of cTBS treatment delivered using a MagStim Rapid stimulator (Magstim Company Ltd.) with a 70-mm air-cooled figure-of-eight coil.
38-1	6410-6414	From	_
38-2	6415-6418	the	_
38-3	6419-6422	2nd	_
38-4	6423-6425	to	_
38-5	6426-6430	16th	_
38-6	6431-6434	day	_
38-7	6435-6436	,	_
38-8	6437-6449	participants	_
38-9	6450-6458	received	_
38-10	6459-6460	3	_
38-11	6461-6466	daily	_
38-12	6467-6475	sessions	_
38-13	6476-6478	of	_
38-14	6479-6483	cTBS	_
38-15	6484-6493	treatment	_
38-16	6494-6503	delivered	_
38-17	6504-6509	using	_
38-18	6510-6511	a	_
38-19	6512-6519	MagStim	http://maven.renci.org/NeuroBridge/neurobridge#StimulantDependence
38-20	6520-6525	Rapid	http://maven.renci.org/NeuroBridge/neurobridge#StimulantDependence
38-21	6526-6536	stimulator	http://maven.renci.org/NeuroBridge/neurobridge#StimulantDependence
38-22	6537-6538	(	_
38-23	6539-6546	Magstim	_
38-24	6547-6554	Company	_
38-25	6555-6559	Ltd.	_
38-26	6560-6561	)	_
38-27	6562-6566	with	_
38-28	6567-6568	a	_
38-29	6569-6574	70-mm	_
38-30	6575-6585	air-cooled	_
38-31	6586-6601	figure-of-eight	_
38-32	6602-6606	coil	_
38-33	6607-6608	.	_

Text=One session of cTBS was 40 seconds in duration and consisted of 3-pulse bursts at 50 Hz repeated every 200 milliseconds (5 Hz) until a total of 600 pulses was reached.
39-1	6609-6612	One	_
39-2	6613-6620	session	_
39-3	6621-6623	of	_
39-4	6624-6628	cTBS	_
39-5	6629-6632	was	_
39-6	6633-6635	40	_
39-7	6636-6643	seconds	_
39-8	6644-6646	in	_
39-9	6647-6655	duration	_
39-10	6656-6659	and	_
39-11	6660-6669	consisted	_
39-12	6670-6672	of	_
39-13	6673-6680	3-pulse	_
39-14	6681-6687	bursts	_
39-15	6688-6690	at	_
39-16	6691-6693	50	_
39-17	6694-6696	Hz	_
39-18	6697-6705	repeated	_
39-19	6706-6711	every	_
39-20	6712-6715	200	_
39-21	6716-6728	milliseconds	_
39-22	6729-6730	(	_
39-23	6731-6732	5	_
39-24	6733-6735	Hz	_
39-25	6736-6737	)	_
39-26	6738-6743	until	_
39-27	6744-6745	a	_
39-28	6746-6751	total	_
39-29	6752-6754	of	_
39-30	6755-6758	600	_
39-31	6759-6765	pulses	_
39-32	6766-6769	was	_
39-33	6770-6777	reached	_
39-34	6778-6779	.	_

Text=To achieve cumulative aftereffects, this protocol was repeated 3 times and (1800 pulses in total) separated by two 15-minute breaks (controlled by a stopwatch) in line with previous methodological studies.
40-1	6780-6782	To	_
40-2	6783-6790	achieve	_
40-3	6791-6801	cumulative	_
40-4	6802-6814	aftereffects	_
40-5	6815-6816	,	_
40-6	6817-6821	this	_
40-7	6822-6830	protocol	_
40-8	6831-6834	was	_
40-9	6835-6843	repeated	_
40-10	6844-6845	3	_
40-11	6846-6851	times	_
40-12	6852-6855	and	_
40-13	6856-6857	(	_
40-14	6858-6862	1800	_
40-15	6863-6869	pulses	_
40-16	6870-6872	in	_
40-17	6873-6878	total	_
40-18	6879-6880	)	_
40-19	6881-6890	separated	_
40-20	6891-6893	by	_
40-21	6894-6897	two	_
40-22	6898-6907	15-minute	_
40-23	6908-6914	breaks	_
40-24	6915-6916	(	_
40-25	6917-6927	controlled	_
40-26	6928-6930	by	_
40-27	6931-6932	a	_
40-28	6933-6942	stopwatch	_
40-29	6943-6944	)	_
40-30	6945-6947	in	_
40-31	6948-6952	line	_
40-32	6953-6957	with	_
40-33	6958-6966	previous	_
40-34	6967-6981	methodological	_
40-35	6982-6989	studies	_
40-36	6990-6991	.	_

Text=The researchers delivered cTBS at 80% of the resting motor threshold (RMT) or the highest intensity the stimulator could deliver for this protocol (50% of maximum output).
41-1	6992-6995	The	_
41-2	6996-7007	researchers	_
41-3	7008-7017	delivered	_
41-4	7018-7022	cTBS	_
41-5	7023-7025	at	_
41-6	7026-7028	80	_
41-7	7029-7030	%	_
41-8	7031-7033	of	_
41-9	7034-7037	the	_
41-10	7038-7045	resting	_
41-11	7046-7051	motor	_
41-12	7052-7061	threshold	_
41-13	7062-7063	(	_
41-14	7064-7067	RMT	_
41-15	7068-7069	)	_
41-16	7070-7072	or	_
41-17	7073-7076	the	_
41-18	7077-7084	highest	_
41-19	7085-7094	intensity	_
41-20	7095-7098	the	_
41-21	7099-7109	stimulator	_
41-22	7110-7115	could	_
41-23	7116-7123	deliver	_
41-24	7124-7127	for	_
41-25	7128-7132	this	_
41-26	7133-7141	protocol	_
41-27	7142-7143	(	_
41-28	7144-7146	50	_
41-29	7147-7148	%	_
41-30	7149-7151	of	_
41-31	7152-7159	maximum	_
41-32	7160-7166	output	_
41-33	7167-7168	)	_
41-34	7169-7170	.	_

Text=The RMT was determined at each visit according to a 5-step procedure.
42-1	7171-7174	The	_
42-2	7175-7178	RMT	_
42-3	7179-7182	was	_
42-4	7183-7193	determined	_
42-5	7194-7196	at	_
42-6	7197-7201	each	_
42-7	7202-7207	visit	_
42-8	7208-7217	according	_
42-9	7218-7220	to	_
42-10	7221-7222	a	_
42-11	7223-7229	5-step	_
42-12	7230-7239	procedure	_
42-13	7240-7241	.	_

Text=The stimulation target, the left TPJ, was defined as a sphere of 6-mm radius centered at Montreal Neurological Institute (MNI) coordinates [−51, −31, 23].
43-1	7242-7245	The	_
43-2	7246-7257	stimulation	_
43-3	7258-7264	target	_
43-4	7265-7266	,	_
43-5	7267-7270	the	_
43-6	7271-7275	left	_
43-7	7276-7279	TPJ	_
43-8	7280-7281	,	_
43-9	7282-7285	was	_
43-10	7286-7293	defined	_
43-11	7294-7296	as	_
43-12	7297-7298	a	_
43-13	7299-7305	sphere	_
43-14	7306-7308	of	_
43-15	7309-7313	6-mm	_
43-16	7314-7320	radius	_
43-17	7321-7329	centered	_
43-18	7330-7332	at	_
43-19	7333-7341	Montreal	_
43-20	7342-7354	Neurological	_
43-21	7355-7364	Institute	_
43-22	7365-7366	(	_
43-23	7367-7370	MNI	_
43-24	7371-7372	)	_
43-25	7373-7384	coordinates	_
43-26	7385-7386	[	_
43-27	7387-7390	−51	_
43-28	7391-7392	,	_
43-29	7393-7396	−31	_
43-30	7397-7398	,	_
43-31	7399-7401	23	_
43-32	7402-7403	]	_
43-33	7404-7405	.	_

Text=This target was transformed into each participant ’ s T1 space by applying an inverse matrix produced during T1 segmentation in SPM (www.fil.ion.ucl.ac.uk/spm) and TMStarget software.
44-1	7406-7410	This	_
44-2	7411-7417	target	_
44-3	7418-7421	was	_
44-4	7422-7433	transformed	_
44-5	7434-7438	into	_
44-6	7439-7443	each	_
44-7	7444-7455	participant	_
44-8	7456-7457	’	_
44-9	7458-7459	s	_
44-10	7460-7462	T1	_
44-11	7463-7468	space	_
44-12	7469-7471	by	_
44-13	7472-7480	applying	_
44-14	7481-7483	an	_
44-15	7484-7491	inverse	_
44-16	7492-7498	matrix	_
44-17	7499-7507	produced	_
44-18	7508-7514	during	_
44-19	7515-7517	T1	_
44-20	7518-7530	segmentation	_
44-21	7531-7533	in	_
44-22	7534-7537	SPM	_
44-23	7538-7539	(	_
44-24	7540-7565	www.fil.ion.ucl.ac.uk/spm	_
44-25	7566-7567	)	_
44-26	7568-7571	and	_
44-27	7572-7581	TMStarget	_
44-28	7582-7590	software	_
44-29	7591-7592	.	_

Text=Then, each individual ’ s target was imported into a frameless neuronavigation system (Visor 2.0, Advanced Neuro Technologies).
45-1	7593-7597	Then	_
45-2	7598-7599	,	_
45-3	7600-7604	each	_
45-4	7605-7615	individual	_
45-5	7616-7617	’	_
45-6	7618-7619	s	_
45-7	7620-7626	target	_
45-8	7627-7630	was	_
45-9	7631-7639	imported	_
45-10	7640-7644	into	_
45-11	7645-7646	a	_
45-12	7647-7656	frameless	_
45-13	7657-7672	neuronavigation	_
45-14	7673-7679	system	_
45-15	7680-7681	(	_
45-16	7682-7687	Visor	_
45-17	7688-7691	2.0	_
45-18	7692-7693	,	_
45-19	7694-7702	Advanced	_
45-20	7703-7708	Neuro	_
45-21	7709-7721	Technologies	_
45-22	7722-7723	)	_
45-23	7724-7725	.	_

Text=The coil was held tangentially to the skull pointing forward, with the center over the target sphere.
46-1	7726-7729	The	_
46-2	7730-7734	coil	_
46-3	7735-7738	was	_
46-4	7739-7743	held	_
46-5	7744-7756	tangentially	_
46-6	7757-7759	to	_
46-7	7760-7763	the	_
46-8	7764-7769	skull	_
46-9	7770-7778	pointing	_
46-10	7779-7786	forward	_
46-11	7787-7788	,	_
46-12	7789-7793	with	_
46-13	7794-7797	the	_
46-14	7798-7804	center	_
46-15	7805-7809	over	_
46-16	7810-7813	the	_
46-17	7814-7820	target	_
46-18	7821-7827	sphere	_
46-19	7828-7829	.	_

Text=Patients in the sham control group received the same rTMS protocol and treatment duration as the real rTMS group.
47-1	7830-7838	Patients	_
47-2	7839-7841	in	_
47-3	7842-7845	the	_
47-4	7846-7850	sham	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
47-5	7851-7858	control	_
47-6	7859-7864	group	_
47-7	7865-7873	received	_
47-8	7874-7877	the	_
47-9	7878-7882	same	_
47-10	7883-7887	rTMS	_
47-11	7888-7896	protocol	_
47-12	7897-7900	and	_
47-13	7901-7910	treatment	_
47-14	7911-7919	duration	_
47-15	7920-7922	as	_
47-16	7923-7926	the	_
47-17	7927-7931	real	_
47-18	7932-7936	rTMS	_
47-19	7937-7942	group	_
47-20	7943-7944	.	_

Text=The only difference was the usage of a sham coil (Magstim Company Ltd.) that produced a similar feeling on the participant ’ s scalp as the real coil but did not induce a current in the cortex.
48-1	7945-7948	The	_
48-2	7949-7953	only	_
48-3	7954-7964	difference	_
48-4	7965-7968	was	_
48-5	7969-7972	the	_
48-6	7973-7978	usage	_
48-7	7979-7981	of	_
48-8	7982-7983	a	_
48-9	7984-7988	sham	_
48-10	7989-7993	coil	_
48-11	7994-7995	(	_
48-12	7996-8003	Magstim	_
48-13	8004-8011	Company	_
48-14	8012-8016	Ltd.	_
48-15	8017-8018	)	_
48-16	8019-8023	that	_
48-17	8024-8032	produced	_
48-18	8033-8034	a	_
48-19	8035-8042	similar	_
48-20	8043-8050	feeling	_
48-21	8051-8053	on	_
48-22	8054-8057	the	_
48-23	8058-8069	participant	_
48-24	8070-8071	’	_
48-25	8072-8073	s	_
48-26	8074-8079	scalp	_
48-27	8080-8082	as	_
48-28	8083-8086	the	_
48-29	8087-8091	real	_
48-30	8092-8096	coil	_
48-31	8097-8100	but	_
48-32	8101-8104	did	_
48-33	8105-8108	not	_
48-34	8109-8115	induce	_
48-35	8116-8117	a	_
48-36	8118-8125	current	_
48-37	8126-8128	in	_
48-38	8129-8132	the	_
48-39	8133-8139	cortex	_
48-40	8140-8141	.	_

Text=Clinical Symptom and Neuropsychological Assessments Clinical symptoms of all patients were graded according to the Positive and Negative Syndrome Scale (PANSS).
49-1	8142-8150	Clinical	_
49-2	8151-8158	Symptom	_
49-3	8159-8162	and	_
49-4	8163-8181	Neuropsychological	_
49-5	8182-8193	Assessments	_
49-6	8194-8202	Clinical	_
49-7	8203-8211	symptoms	_
49-8	8212-8214	of	_
49-9	8215-8218	all	_
49-10	8219-8227	patients	_
49-11	8228-8232	were	_
49-12	8233-8239	graded	_
49-13	8240-8249	according	_
49-14	8250-8252	to	_
49-15	8253-8256	the	_
49-16	8257-8265	Positive	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
49-17	8266-8269	and	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
49-18	8270-8278	Negative	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
49-19	8279-8287	Syndrome	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
49-20	8288-8293	Scale	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
49-21	8294-8295	(	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
49-22	8296-8301	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
49-23	8302-8303	)	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
49-24	8304-8305	.	_

Text=In addition, all patients and HCs were evaluated using standardized neuropsychological tests (supplementary tables E1 and E2).
50-1	8306-8308	In	_
50-2	8309-8317	addition	_
50-3	8318-8319	,	_
50-4	8320-8323	all	_
50-5	8324-8332	patients	_
50-6	8333-8336	and	_
50-7	8337-8340	HCs	http://maven.renci.org/NeuroBridge/neurobridge#Thing
50-8	8341-8345	were	_
50-9	8346-8355	evaluated	_
50-10	8356-8361	using	_
50-11	8362-8374	standardized	_
50-12	8375-8393	neuropsychological	_
50-13	8394-8399	tests	_
50-14	8400-8401	(	_
50-15	8402-8415	supplementary	_
50-16	8416-8422	tables	_
50-17	8423-8425	E1	_
50-18	8426-8429	and	_
50-19	8430-8432	E2	_
50-20	8433-8434	)	_
50-21	8435-8436	.	_

Text=For AVH patients participating in the rTMS study, the primary outcome was the Auditory Hallucination Rating Scale (AHRS), which would be administered with other measures on the 1st and 17th visits.
51-1	8437-8440	For	_
51-2	8441-8444	AVH	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
51-3	8445-8453	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
51-4	8454-8467	participating	_
51-5	8468-8470	in	_
51-6	8471-8474	the	_
51-7	8475-8479	rTMS	http://maven.renci.org/NeuroBridge/neurobridge#Thing
51-8	8480-8485	study	_
51-9	8486-8487	,	_
51-10	8488-8491	the	_
51-11	8492-8499	primary	_
51-12	8500-8507	outcome	_
51-13	8508-8511	was	_
51-14	8512-8515	the	_
51-15	8516-8524	Auditory	http://maven.renci.org/NeuroBridge/neurobridge#AuditoryHallucinationsSubscaleofPsychoticSymptomsRatingScale
51-16	8525-8538	Hallucination	http://maven.renci.org/NeuroBridge/neurobridge#AuditoryHallucinationsSubscaleofPsychoticSymptomsRatingScale
51-17	8539-8545	Rating	http://maven.renci.org/NeuroBridge/neurobridge#AuditoryHallucinationsSubscaleofPsychoticSymptomsRatingScale
51-18	8546-8551	Scale	http://maven.renci.org/NeuroBridge/neurobridge#AuditoryHallucinationsSubscaleofPsychoticSymptomsRatingScale
51-19	8552-8553	(	http://maven.renci.org/NeuroBridge/neurobridge#AuditoryHallucinationsSubscaleofPsychoticSymptomsRatingScale
51-20	8554-8558	AHRS	http://maven.renci.org/NeuroBridge/neurobridge#AuditoryHallucinationsSubscaleofPsychoticSymptomsRatingScale
51-21	8559-8560	)	http://maven.renci.org/NeuroBridge/neurobridge#AuditoryHallucinationsSubscaleofPsychoticSymptomsRatingScale
51-22	8561-8562	,	_
51-23	8563-8568	which	_
51-24	8569-8574	would	_
51-25	8575-8577	be	_
51-26	8578-8590	administered	_
51-27	8591-8595	with	_
51-28	8596-8601	other	_
51-29	8602-8610	measures	_
51-30	8611-8613	on	_
51-31	8614-8617	the	_
51-32	8618-8621	1st	_
51-33	8622-8625	and	_
51-34	8626-8630	17th	_
51-35	8631-8637	visits	_
51-36	8638-8639	.	_

Text=MRI Data Processing Functional image processing was carried out using the DPARSF (http: //rfmri.org) and SPM (www.fil.ion.ucl.ac.uk/spm) toolkits.
52-1	8640-8643	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
52-2	8644-8648	Data	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
52-3	8649-8659	Processing	_
52-4	8660-8670	Functional	_
52-5	8671-8676	image	_
52-6	8677-8687	processing	_
52-7	8688-8691	was	_
52-8	8692-8699	carried	_
52-9	8700-8703	out	_
52-10	8704-8709	using	_
52-11	8710-8713	the	_
52-12	8714-8720	DPARSF	_
52-13	8721-8722	(	_
52-14	8723-8727	http	_
52-15	8728-8729	:	_
52-16	8730-8741	//rfmri.org	_
52-17	8742-8743	)	_
52-18	8744-8747	and	_
52-19	8748-8751	SPM	_
52-20	8752-8753	(	_
52-21	8754-8779	www.fil.ion.ucl.ac.uk/spm	_
52-22	8780-8781	)	_
52-23	8782-8790	toolkits	_
52-24	8791-8792	.	_

Text=The preprocessing included (1) deleting the first 5 volumes; (2) slice timing and realignment; (3) co-registering T1 to functional images; (4) normalizing T1 to the MNI space and segmenting it into gray matter, white matter, and cerebrospinal fluid (spatial resolution: 3 × 3 × 3); (5) smoothing images with a 4-mm isotropic Gaussian kernel; (6) filtering temporal bandpass (0.01–0.1 Hz), and regressing out 15 nuisance signals (global mean, white matter, cerebrospinal fluid signals, and 24 head-motion parameters.
53-1	8793-8796	The	_
53-2	8797-8810	preprocessing	_
53-3	8811-8819	included	_
53-4	8820-8821	(	_
53-5	8822-8823	1	_
53-6	8824-8825	)	_
53-7	8826-8834	deleting	_
53-8	8835-8838	the	_
53-9	8839-8844	first	_
53-10	8845-8846	5	_
53-11	8847-8854	volumes	_
53-12	8855-8856	;	_
53-13	8857-8858	(	_
53-14	8859-8860	2	_
53-15	8861-8862	)	_
53-16	8863-8868	slice	_
53-17	8869-8875	timing	_
53-18	8876-8879	and	_
53-19	8880-8891	realignment	_
53-20	8892-8893	;	_
53-21	8894-8895	(	_
53-22	8896-8897	3	_
53-23	8898-8899	)	_
53-24	8900-8914	co-registering	_
53-25	8915-8917	T1	_
53-26	8918-8920	to	_
53-27	8921-8931	functional	_
53-28	8932-8938	images	_
53-29	8939-8940	;	_
53-30	8941-8942	(	_
53-31	8943-8944	4	_
53-32	8945-8946	)	_
53-33	8947-8958	normalizing	_
53-34	8959-8961	T1	_
53-35	8962-8964	to	_
53-36	8965-8968	the	_
53-37	8969-8972	MNI	_
53-38	8973-8978	space	_
53-39	8979-8982	and	_
53-40	8983-8993	segmenting	_
53-41	8994-8996	it	_
53-42	8997-9001	into	_
53-43	9002-9006	gray	_
53-44	9007-9013	matter	_
53-45	9014-9015	,	_
53-46	9016-9021	white	_
53-47	9022-9028	matter	_
53-48	9029-9030	,	_
53-49	9031-9034	and	_
53-50	9035-9048	cerebrospinal	_
53-51	9049-9054	fluid	_
53-52	9055-9056	(	_
53-53	9057-9064	spatial	_
53-54	9065-9075	resolution	_
53-55	9076-9077	:	_
53-56	9078-9079	3	_
53-57	9080-9081	×	_
53-58	9082-9083	3	_
53-59	9084-9085	×	_
53-60	9086-9087	3	_
53-61	9088-9089	)	_
53-62	9090-9091	;	_
53-63	9092-9093	(	_
53-64	9094-9095	5	_
53-65	9096-9097	)	_
53-66	9098-9107	smoothing	_
53-67	9108-9114	images	_
53-68	9115-9119	with	_
53-69	9120-9121	a	_
53-70	9122-9126	4-mm	_
53-71	9127-9136	isotropic	_
53-72	9137-9145	Gaussian	_
53-73	9146-9152	kernel	_
53-74	9153-9154	;	_
53-75	9155-9156	(	_
53-76	9157-9158	6	_
53-77	9159-9160	)	_
53-78	9161-9170	filtering	_
53-79	9171-9179	temporal	_
53-80	9180-9188	bandpass	_
53-81	9189-9190	(	_
53-82	9191-9199	0.01–0.1	_
53-83	9200-9202	Hz	_
53-84	9203-9204	)	_
53-85	9205-9206	,	_
53-86	9207-9210	and	_
53-87	9211-9221	regressing	_
53-88	9222-9225	out	_
53-89	9226-9228	15	_
53-90	9229-9237	nuisance	_
53-91	9238-9245	signals	_
53-92	9246-9247	(	_
53-93	9248-9254	global	_
53-94	9255-9259	mean	_
53-95	9260-9261	,	_
53-96	9262-9267	white	_
53-97	9268-9274	matter	_
53-98	9275-9276	,	_
53-99	9277-9290	cerebrospinal	_
53-100	9291-9296	fluid	_
53-101	9297-9304	signals	_
53-102	9305-9306	,	_
53-103	9307-9310	and	_
53-104	9311-9313	24	_
53-105	9314-9325	head-motion	_
53-106	9326-9336	parameters	_
53-107	9337-9338	.	_

Text=Subsequently, Pearson ’ s correlations were conducted between the time series of all pairs of voxels to construct a whole-brain matrix for each participant.
54-1	9339-9351	Subsequently	_
54-2	9352-9353	,	_
54-3	9354-9361	Pearson	_
54-4	9362-9363	’	_
54-5	9364-9365	s	_
54-6	9366-9378	correlations	_
54-7	9379-9383	were	_
54-8	9384-9393	conducted	_
54-9	9394-9401	between	_
54-10	9402-9405	the	_
54-11	9406-9410	time	_
54-12	9411-9417	series	_
54-13	9418-9420	of	_
54-14	9421-9424	all	_
54-15	9425-9430	pairs	_
54-16	9431-9433	of	_
54-17	9434-9440	voxels	_
54-18	9441-9443	to	_
54-19	9444-9453	construct	_
54-20	9454-9455	a	_
54-21	9456-9467	whole-brain	_
54-22	9468-9474	matrix	_
54-23	9475-9478	for	_
54-24	9479-9483	each	_
54-25	9484-9495	participant	_
54-26	9496-9497	.	_

Text=Finally, functional connectivity strength (FCS) defined as the sum of the coefficients between a given voxel and all other voxels, was then standardized by dividing by the average whole-brain FCS value.
55-1	9498-9505	Finally	_
55-2	9506-9507	,	_
55-3	9508-9518	functional	_
55-4	9519-9531	connectivity	_
55-5	9532-9540	strength	_
55-6	9541-9542	(	_
55-7	9543-9546	FCS	_
55-8	9547-9548	)	_
55-9	9549-9556	defined	_
55-10	9557-9559	as	_
55-11	9560-9563	the	_
55-12	9564-9567	sum	_
55-13	9568-9570	of	_
55-14	9571-9574	the	_
55-15	9575-9587	coefficients	_
55-16	9588-9595	between	_
55-17	9596-9597	a	_
55-18	9598-9603	given	_
55-19	9604-9609	voxel	_
55-20	9610-9613	and	_
55-21	9614-9617	all	_
55-22	9618-9623	other	_
55-23	9624-9630	voxels	_
55-24	9631-9632	,	_
55-25	9633-9636	was	_
55-26	9637-9641	then	_
55-27	9642-9654	standardized	_
55-28	9655-9657	by	_
55-29	9658-9666	dividing	_
55-30	9667-9669	by	_
55-31	9670-9673	the	_
55-32	9674-9681	average	_
55-33	9682-9693	whole-brain	_
55-34	9694-9697	FCS	_
55-35	9698-9703	value	_
55-36	9704-9705	.	_

Text=To eliminate voxels with weak correlations attributable to signal noise, the analysis was restricted to positive correlations (r>.25, P <.001).
56-1	9706-9708	To	_
56-2	9709-9718	eliminate	_
56-3	9719-9725	voxels	_
56-4	9726-9730	with	_
56-5	9731-9735	weak	_
56-6	9736-9748	correlations	_
56-7	9749-9761	attributable	_
56-8	9762-9764	to	_
56-9	9765-9771	signal	_
56-10	9772-9777	noise	_
56-11	9778-9779	,	_
56-12	9780-9783	the	_
56-13	9784-9792	analysis	_
56-14	9793-9796	was	_
56-15	9797-9807	restricted	_
56-16	9808-9810	to	_
56-17	9811-9819	positive	_
56-18	9820-9832	correlations	_
56-19	9833-9834	(	_
56-20	9835-9836	r	_
56-21	9837-9838	>	_
56-22	9839-9842	.25	_
56-23	9843-9844	,	_
56-24	9845-9846	P	_
56-25	9847-9848	<	_
56-26	9849-9853	.001	_
56-27	9854-9855	)	_
56-28	9856-9857	.	_

Text=Statistical Analysis For the cross-sectional study, demographic characteristics, neuropsychological scores, and imaging features were compared between the 3 groups by one-way analysis of variance (ANOVA).
57-1	9858-9869	Statistical	_
57-2	9870-9878	Analysis	_
57-3	9879-9882	For	_
57-4	9883-9886	the	_
57-5	9887-9902	cross-sectional	_
57-6	9903-9908	study	_
57-7	9909-9910	,	_
57-8	9911-9922	demographic	_
57-9	9923-9938	characteristics	_
57-10	9939-9940	,	_
57-11	9941-9959	neuropsychological	_
57-12	9960-9966	scores	_
57-13	9967-9968	,	_
57-14	9969-9972	and	_
57-15	9973-9980	imaging	_
57-16	9981-9989	features	_
57-17	9990-9994	were	_
57-18	9995-10003	compared	_
57-19	10004-10011	between	_
57-20	10012-10015	the	_
57-21	10016-10017	3	_
57-22	10018-10024	groups	_
57-23	10025-10027	by	_
57-24	10028-10035	one-way	_
57-25	10036-10044	analysis	_
57-26	10045-10047	of	_
57-27	10048-10056	variance	_
57-28	10057-10058	(	_
57-29	10059-10064	ANOVA	_
57-30	10065-10066	)	_
57-31	10067-10068	.	_

Text=Notably, outliers in neuropsychological scores were identified before ANOVA by nonlinear regression analyses in GraphPad Prism.
58-1	10069-10076	Notably	_
58-2	10077-10078	,	_
58-3	10079-10087	outliers	_
58-4	10088-10090	in	_
58-5	10091-10109	neuropsychological	_
58-6	10110-10116	scores	_
58-7	10117-10121	were	_
58-8	10122-10132	identified	_
58-9	10133-10139	before	_
58-10	10140-10145	ANOVA	_
58-11	10146-10148	by	_
58-12	10149-10158	nonlinear	_
58-13	10159-10169	regression	_
58-14	10170-10178	analyses	_
58-15	10179-10181	in	_
58-16	10182-10190	GraphPad	_
58-17	10191-10196	Prism	_
58-18	10197-10198	.	_

Text=The Bonferroni or Tamhane ’ s test was used for pair-wise post hoc comparisons.
59-1	10199-10202	The	_
59-2	10203-10213	Bonferroni	_
59-3	10214-10216	or	_
59-4	10217-10224	Tamhane	_
59-5	10225-10226	’	_
59-6	10227-10228	s	_
59-7	10229-10233	test	_
59-8	10234-10237	was	_
59-9	10238-10242	used	_
59-10	10243-10246	for	_
59-11	10247-10256	pair-wise	_
59-12	10257-10261	post	_
59-13	10262-10265	hoc	_
59-14	10266-10277	comparisons	_
59-15	10278-10279	.	_

Text=Clinical characteristics were compared between patient groups using 2-sample t-tests.
60-1	10280-10288	Clinical	_
60-2	10289-10304	characteristics	_
60-3	10305-10309	were	_
60-4	10310-10318	compared	_
60-5	10319-10326	between	_
60-6	10327-10334	patient	_
60-7	10335-10341	groups	_
60-8	10342-10347	using	_
60-9	10348-10356	2-sample	_
60-10	10357-10364	t-tests	_
60-11	10365-10366	.	_

Text=In the longitudinal study, the change in clinical symptom was analyzed by 2-way (group by time) ANOVA.
61-1	10367-10369	In	_
61-2	10370-10373	the	_
61-3	10374-10386	longitudinal	_
61-4	10387-10392	study	_
61-5	10393-10394	,	_
61-6	10395-10398	the	_
61-7	10399-10405	change	_
61-8	10406-10408	in	_
61-9	10409-10417	clinical	_
61-10	10418-10425	symptom	_
61-11	10426-10429	was	_
61-12	10430-10438	analyzed	_
61-13	10439-10441	by	_
61-14	10442-10447	2-way	_
61-15	10448-10449	(	_
61-16	10450-10455	group	_
61-17	10456-10458	by	_
61-18	10459-10463	time	_
61-19	10464-10465	)	_
61-20	10466-10471	ANOVA	_
61-21	10472-10473	.	_

Text=Since the MRI data of real and sham groups were acquired using different scanners, comparisons of pre- or post-treatment data between the groups largely reflect the systematic error of scanners rather than brain functional changes.
62-1	10474-10479	Since	_
62-2	10480-10483	the	_
62-3	10484-10487	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
62-4	10488-10492	data	_
62-5	10493-10495	of	_
62-6	10496-10500	real	_
62-7	10501-10504	and	_
62-8	10505-10509	sham	_
62-9	10510-10516	groups	_
62-10	10517-10521	were	_
62-11	10522-10530	acquired	_
62-12	10531-10536	using	_
62-13	10537-10546	different	_
62-14	10547-10555	scanners	_
62-15	10556-10557	,	_
62-16	10558-10569	comparisons	_
62-17	10570-10572	of	_
62-18	10573-10577	pre-	_
62-19	10578-10580	or	_
62-20	10581-10595	post-treatment	_
62-21	10596-10600	data	_
62-22	10601-10608	between	_
62-23	10609-10612	the	_
62-24	10613-10619	groups	_
62-25	10620-10627	largely	_
62-26	10628-10635	reflect	_
62-27	10636-10639	the	_
62-28	10640-10650	systematic	_
62-29	10651-10656	error	_
62-30	10657-10659	of	_
62-31	10660-10668	scanners	_
62-32	10669-10675	rather	_
62-33	10676-10680	than	_
62-34	10681-10686	brain	_
62-35	10687-10697	functional	_
62-36	10698-10705	changes	_
62-37	10706-10707	.	_

Text=However, the pre- to post-treatment alteration is comparable, since the scanner effect could be well controlled by the within center subtraction (post- minus pre-state).
63-1	10708-10715	However	_
63-2	10716-10717	,	_
63-3	10718-10721	the	_
63-4	10722-10726	pre-	_
63-5	10727-10729	to	_
63-6	10730-10744	post-treatment	_
63-7	10745-10755	alteration	_
63-8	10756-10758	is	_
63-9	10759-10769	comparable	_
63-10	10770-10771	,	_
63-11	10772-10777	since	_
63-12	10778-10781	the	_
63-13	10782-10789	scanner	_
63-14	10790-10796	effect	_
63-15	10797-10802	could	_
63-16	10803-10805	be	_
63-17	10806-10810	well	_
63-18	10811-10821	controlled	_
63-19	10822-10824	by	_
63-20	10825-10828	the	_
63-21	10829-10835	within	_
63-22	10836-10842	center	_
63-23	10843-10854	subtraction	_
63-24	10855-10856	(	_
63-25	10857-10862	post-	_
63-26	10863-10868	minus	_
63-27	10869-10878	pre-state	_
63-28	10879-10880	)	_
63-29	10881-10882	.	_

Text=Thus, the FCS changes following treatment were compared between groups by 2-sample t-test.
64-1	10883-10887	Thus	_
64-2	10888-10889	,	_
64-3	10890-10893	the	_
64-4	10894-10897	FCS	_
64-5	10898-10905	changes	_
64-6	10906-10915	following	_
64-7	10916-10925	treatment	_
64-8	10926-10930	were	_
64-9	10931-10939	compared	_
64-10	10940-10947	between	_
64-11	10948-10954	groups	_
64-12	10955-10957	by	_
64-13	10958-10966	2-sample	_
64-14	10967-10973	t-test	_
64-15	10974-10975	.	_

Text=All voxel-based imaging analyses were corrected by Gaussian Random Field (GRF) theory (cluster-defined threshold, P <.05, cluster-level corrected P <.05).
65-1	10976-10979	All	_
65-2	10980-10991	voxel-based	_
65-3	10992-10999	imaging	_
65-4	11000-11008	analyses	_
65-5	11009-11013	were	_
65-6	11014-11023	corrected	_
65-7	11024-11026	by	_
65-8	11027-11035	Gaussian	_
65-9	11036-11042	Random	_
65-10	11043-11048	Field	_
65-11	11049-11050	(	_
65-12	11051-11054	GRF	_
65-13	11055-11056	)	_
65-14	11057-11063	theory	_
65-15	11064-11065	(	_
65-16	11066-11081	cluster-defined	_
65-17	11082-11091	threshold	_
65-18	11092-11093	,	_
65-19	11094-11095	P	_
65-20	11096-11097	<	_
65-21	11098-11101	.05	_
65-22	11102-11103	,	_
65-23	11104-11117	cluster-level	_
65-24	11118-11127	corrected	_
65-25	11128-11129	P	_
65-26	11130-11131	<	_
65-27	11132-11135	.05	_
65-28	11136-11137	)	_
65-29	11138-11139	.	_

Text=Complementary Experiments First, target-to-whole brain functional connectivity was used as a secondary measure.
66-1	11140-11153	Complementary	_
66-2	11154-11165	Experiments	_
66-3	11166-11171	First	_
66-4	11172-11173	,	_
66-5	11174-11189	target-to-whole	_
66-6	11190-11195	brain	_
66-7	11196-11206	functional	_
66-8	11207-11219	connectivity	_
66-9	11220-11223	was	_
66-10	11224-11228	used	_
66-11	11229-11231	as	_
66-12	11232-11233	a	_
66-13	11234-11243	secondary	_
66-14	11244-11251	measure	_
66-15	11252-11253	.	_

Text=Second, longitudinal data of 2 HC groups from 2 scanning sites were utilized to clarify whether the MRI findings for the TMS effect were influenced by scanner.
67-1	11254-11260	Second	_
67-2	11261-11262	,	_
67-3	11263-11275	longitudinal	_
67-4	11276-11280	data	_
67-5	11281-11283	of	_
67-6	11284-11285	2	_
67-7	11286-11288	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
67-8	11289-11295	groups	_
67-9	11296-11300	from	_
67-10	11301-11302	2	_
67-11	11303-11311	scanning	_
67-12	11312-11317	sites	_
67-13	11318-11322	were	_
67-14	11323-11331	utilized	_
67-15	11332-11334	to	_
67-16	11335-11342	clarify	_
67-17	11343-11350	whether	_
67-18	11351-11354	the	_
67-19	11355-11358	MRI	_
67-20	11359-11367	findings	_
67-21	11368-11371	for	_
67-22	11372-11375	the	_
67-23	11376-11379	TMS	_
67-24	11380-11386	effect	_
67-25	11387-11391	were	_
67-26	11392-11402	influenced	_
67-27	11403-11405	by	_
67-28	11406-11413	scanner	_
67-29	11414-11415	.	_

Text=Third, we re-computed the FCS for correlations> 0 to test the robustness of the findings.
68-1	11416-11421	Third	_
68-2	11422-11423	,	_
68-3	11424-11426	we	_
68-4	11427-11438	re-computed	_
68-5	11439-11442	the	_
68-6	11443-11446	FCS	_
68-7	11447-11450	for	_
68-8	11451-11463	correlations	_
68-9	11464-11465	>	_
68-10	11466-11467	0	_
68-11	11468-11470	to	_
68-12	11471-11475	test	_
68-13	11476-11479	the	_
68-14	11480-11490	robustness	_
68-15	11491-11493	of	_
68-16	11494-11497	the	_
68-17	11498-11506	findings	_
68-18	11507-11508	.	_

Text=Fourth, all image-based statistical analyses were corrected for multiple comparisons using Threshold-Free Cluster Enhancement in FSL software (corrected P <.05).
69-1	11509-11515	Fourth	_
69-2	11516-11517	,	_
69-3	11518-11521	all	_
69-4	11522-11533	image-based	_
69-5	11534-11545	statistical	_
69-6	11546-11554	analyses	_
69-7	11555-11559	were	_
69-8	11560-11569	corrected	_
69-9	11570-11573	for	_
69-10	11574-11582	multiple	_
69-11	11583-11594	comparisons	_
69-12	11595-11600	using	_
69-13	11601-11615	Threshold-Free	_
69-14	11616-11623	Cluster	_
69-15	11624-11635	Enhancement	_
69-16	11636-11638	in	_
69-17	11639-11642	FSL	_
69-18	11643-11651	software	_
69-19	11652-11653	(	_
69-20	11654-11663	corrected	_
69-21	11664-11665	P	_
69-22	11666-11667	<	_
69-23	11668-11671	.05	_
69-24	11672-11673	)	_
69-25	11674-11675	.	_

Text=See details of these experiments in supplementary materials.
70-1	11676-11679	See	_
70-2	11680-11687	details	_
70-3	11688-11690	of	_
70-4	11691-11696	these	_
70-5	11697-11708	experiments	_
70-6	11709-11711	in	_
70-7	11712-11725	supplementary	_
70-8	11726-11735	materials	_
70-9	11736-11737	.	_

